Linnaeus Therapeutics, Inc.
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
Solid Tumor, Adult
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER in Solid Tumor, Adult are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT04130516: Phase 2 trial, sponsor Linnaeus Therapeutics, Inc., drug LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER. Primary completion date 2026-12-31 (estimated).”